` SPRO (Spero Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

SPRO
vs
S&P 500

Over the past 12 months, SPRO has significantly outperformed S&P 500, delivering a return of +176% compared to the S&P 500's +16% growth.

Stocks Performance
SPRO vs S&P 500

Loading
SPRO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SPRO vs S&P 500

Loading
SPRO
S&P 500
Difference
www.alphaspread.com

Performance By Year
SPRO vs S&P 500

Loading
SPRO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Spero Therapeutics Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Spero Therapeutics Inc
Glance View

Market Cap
125.1m USD
Industry
Biotechnology

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

SPRO Intrinsic Value
0.33 USD
Overvaluation 85%
Intrinsic Value
Price
Back to Top